Latest Breaking News On - Esperion therapeutics inc - Page 1 : vimarsana.com

Analyzing Esperion Therapeutics (NASDAQ:ESPR) and Clearmind Medicine (NASDAQ:CMND)

Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) and Clearmind Medicine (NASDAQ:CMND – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, profitability, valuation, dividends and risk. Profitability This table compares Esperion Therapeutics and […]

British columbiaUnited statesAnn arborDaiichi sankyo europe gmbCyntar ventures incDaiichi sankyo coOtsuka pharmaceutical co ltdEsperion therapeutics incClearmind medicine incScisparc ltdEsperion therapeuticsGet free reportClearmind medicineGiven esperion therapeuticDaiichi sankyoDaiichi sankyo europe

Clearmind Medicine (NASDAQ:CMND) vs Esperion Therapeutics (NASDAQ:ESPR) Head-To-Head Analysis

Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) and Clearmind Medicine (NASDAQ:CMND – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, institutional ownership and earnings. Analyst Ratings This is a summary of […]

British columbiaAnn arborUnited statesDaiichi sankyo europe gmbScisparc ltdClearmind medicine incCyntar ventures incEsperion therapeutics incDaiichi sankyo coOtsuka pharmaceutical co ltdEsperion therapeuticsGet free reportClearmind medicineGiven esperion therapeuticDaiichi sankyoDaiichi sankyo europe

Esperion Therapeutics (NASDAQ:ESPR) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) in a report issued on Tuesday, Benzinga reports. They currently have a $16.00 target price on the biopharmaceutical company’s stock. A number of other equities analysts also recently commented on the company. StockNews.com downgraded Esperion Therapeutics from a strong-buy rating […]

Needham companySimplicity wealthEsperion therapeutics incPortfolio partnersHerbst groupEsperion therapeuticsFree reportModerate buyGet free reportEsperion therapeutics daily

Esperion Therapeutics (NASDAQ:ESPR) Earns Buy Rating from HC Wainwright

Esperion Therapeutics (NASDAQ:ESPR) Earns Buy Rating from HC Wainwright
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Simplicity wealthPortfolio partnersHerbst groupNeedham companyEsperion therapeutics incEsperion therapeuticsFree reportModerate buyGet free reportEsperion therapeutics daily

Analysts Set Esperion Therapeutics, Inc (NASDAQ:ESPR) Target Price at $9 33

Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) has been assigned a consensus rating of “Hold” from the five research firms that are currently covering the firm, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year target price […]

Vanguard group incEsperion therapeutics incBellevue groupNeedham companyArmistice capitalEsperion therapeuticsGet free reportMonaco asset managementAsset managementTherapeutics trading downGet freeEsperion therapeutics daily